Abstract: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.

Abstract: The bottom surface of a patient's foot makes contact with the receiving region of a device body to cause a set of temperature sensors to produce a current set of temperature values. Four or more earlier sets of temperature values produced at earlier times for the bottom surface of the patient's foot are accessed. Next, after setting a normalization reference for the earlier sets of temperature values and the current set of temperature values to produce normalized data, the normalized data is transformed into model information representing the progression of PDN or PAD. That model information is used to ascertain the trajectory of the patient's PDN or PAD.

Abstract: The present disclosure provides computer-implemented methods of organising the marketing of a compound that neutralises BTN2A1.

Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.

Abstract: Particular naturally occurring glycosylated acyl-flavonols are now shown to be effective mammalian ?-amylase inhibitors. Such compounds can be obtained from plants of the genus Crocosmia and the compounds are useful in controlling starch digestion such as for management of glycemia in pre-diabetic or diabetic subjects, for management of obesity or for inhibiting oral caries or plaque formation.

Abstract: Particular naturally occurring glycosylated acyl-flavonols, e.g.

Abstract: Novel peptides, nucleic acids encoding them, and derivatives of the peptides are described. The peptides and nucleic acids are of use in modulating ?4 integrin function and in treating ?4 integrin-mediated inflammatory disorders.